TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center.

TRC102 Scientific Presentations

Phase II Trial of TRC102 (methoxyamineHCl) in Combination with Temozolomide (TMZ) in Patients with Advanced Non-Small Cell Lung Cancer
Eads et al Investigational New Drugs 2020 (TRC102 + Temodar Phase 1 trial)
ASCO 2020 Phase 2 TRC102 + Alimta/Phase 1 TRC102 + Alimta + cisplatin Poster
ASCO 2020 TRC102 +chemoradiation in lung cancer Phase 1 Poster
2019 AACR TRC102 + Temodar Phase 2 Poster
2017 ASCO TRC102 + Temodar Phase 1 Poster
2016 ASCO TRC102 + Temodar Phase 1 Poster
2015 ASCO TRC102 + Temozolomide Phase 1 Poster
2015 AACR TRC102 + Temozolomide Phase 1 Poster
2014 ASH TRC102 + Fludarabine Phase 1 Poster
2012 AACR TRC102 + Temodar Phase 1b poster
2012 AACR TRC102 + Temodar Phase 1b PK data poster
2010 ASCO – Phase 1 slideshow
2010 ASCO – Phase 1 poster
2010 AACR– preclinical poster
2009 AACR– 3 preclinical posters
2007 EORTC-NCI-AACR

TRC102 Journal Publications

Wheeler et al, Cancer Cell 2020 Exceptional Responders Paper
Caimi PF, et al. TRC102 + Fludara Phase 1 Trial
Gordon MS et al Investigational New Drugs 2012 (TRC102 Phase 1b)